PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa): A phase III study (CONDOR)—A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth.

Frédéric Pouliot,Michael A. Gorin,Steven P. Rowe,Lawrence Saperstein,David P. Josephson,Peter R. Carroll,Jeffrey Y.C. Wong,Austin R. Pantel,Steve Y. Cho,Kenneth L. Gage,Morand Piert,Andrei Iagaru,Janet Pollard,Vivien Wong,Jessica Jensen,Nancy Stambler,Michael J. Morris,Barry A. Siegel

PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa): A phase III study (CONDOR)—A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth.

2021

Frédéric Pouliot
Michael A. Gorin
Steven P. Rowe
Lawrence Saperstein
David P. Josephson
Peter R. Carroll
Jeffrey Y.C. Wong
Austin R. Pantel
Steve Y. Cho
Kenneth L. Gage
Morand Piert
Andrei Iagaru
Janet Pollard
Vivien Wong
Jessica Jensen
Nancy Stambler
Michael J. Morris
Barry A. Siegel

33Background: PSMA-targeted PET/CT is superior to conventional imaging modalities to localize biochemically recurrent (BCR) PCa after local therapy, particularly in pts with low PSA (<2 ng/mL). How...

Keywords:

PET-CT
in patient
Radiology
Medicine
breakpoint cluster region
imaging modalities
18F-DCFPyL
Recurrent prostate cancer
predictive value

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations